Gish R G
Department of Medicine, California Pacific Medical Center, San Francisco 94115, USA.
Semin Liver Dis. 1999;19 Suppl 1:35-47.
Standards of treatment for patients who are infected with the hepatitis C virus have been developed from national and international consensus conferences, from extensive clinical experience with various regimens, from exhaustive literature reviews, and from opinion leaders in the general medical community. From 1987 until very recently, the standard of treatment for non-A, non-B hepatitis, later defined as hepatitis C, had consisted of alpha interferon monotherapy administered for up to 18 to 24 months. Alpha interferon has been used in a variety of regimens with varying success for the initial treatment of chronic hepatitis C, for the retreatment of patients who have relapsed after responding to interferon, and for the retreatment of alpha interferon nonresponders. Treatment standards have evolved as new agents have become available for use in our treatment armamentarium. The current treatment standards, as well as recommendations for the treatment of specific HCV subgroups, are reviewed.
丙型肝炎病毒感染患者的治疗标准是通过国家和国际共识会议、各种治疗方案的广泛临床经验、详尽的文献综述以及普通医学界的意见领袖制定出来的。从1987年到最近,非甲非乙型肝炎(后来定义为丙型肝炎)的治疗标准一直是使用α干扰素单药治疗,疗程长达18至24个月。α干扰素已被用于多种治疗方案,在慢性丙型肝炎的初始治疗、对干扰素治疗有反应后复发患者的再治疗以及α干扰素无反应者的再治疗中取得了不同程度的成功。随着新药物可用于我们的治疗手段,治疗标准也在不断演变。本文将对当前的治疗标准以及特定丙型肝炎病毒亚组的治疗建议进行综述。